Our editorial board member and EAN Secretary General, Marianne de Visser (Academic Medical Centre, Amsterdam, The Netherlands), shares her expert insight into pregnancy and neuromuscular disorders.
1. How does pregnancy affect the symptoms of neuromuscular disorders? (0:05)
2. What are the implications of neuromuscular disorders and their treatments for the development of the fetus and complications of pregnancy? (1:20)
3. What advice would you give to women with neuromuscular disorders who are or wish to become pregnant? (3:28)
4. What advice would you give to physicians in terms of issues surrounding pregnancy and neuromuscular disorders? (4:30)
5. What are the major unmet needs in this field? (5:39)
Speaker disclosure: Marianne de Visser has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Neuromuscular Diseases
Renato Mantegazza, EAN 2021: Challenges in the Treatment of Myasthenia Gravis
touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy) to discuss the challenges that arise in treating patients with myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was presented at the 7th […]
Jeffrey Guptill, AAN 2021: Vivacity-MG Study Results
We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis. The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab […]
Tahseen Mozaffar: PROPEL Study Results
TouchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!